Pre-made Pritumumab benchmark antibody (Whole mAb, anti-VIM/Vimentin therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-966

Anti-VIM/Vimentin therapeutic antibody (Pre-made Pritumumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Pritumumab (PTB) is a human monoclonal antibody targeted against glioma.[1] It works by binding to the ecto-domain of vimentin on the surface of cancer cells.[1][2] developed by Nascent Biotech.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-966-1mg 1mg 3090
GMP-Bios-INN-966-10mg 10mg Inquiry
GMP-Bios-INN-966-100mg 100mg Inquiry
GMP-Bios-INN-966-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Pritumumab Biosimilar, Whole Mab: Anti-Vim/Vimentin therapeutic antibody
INN Name Pritumumab
TargetVIM
FormatWhole mAb
Derivationhuman
Species Reactivityhuman
CH1 IsotypeIgG1 - nd
VD LCIgG1 - nd
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesNascent Biotech, Inc. (San Diego CA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0